Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga·10/20/2025 12:10:45
Listen to the news
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Monday.
Shares of Olema Pharmaceuticals Inc (NASDAQ:OLMA) fell 18.3% to $7.64 in pre-market trading after the company announced new data from the Phase 1b/2 trial of palazestrant plus ribociclib in ER+/HER2- metastatic breast cancer at ESMO 2025.
Olema Pharmaceuticals shares dipped 18.3% to $7.64 in pre-market trading.
Here are some other stocks moving lower in pre-market trading.
- Concord Medical Services Hldgs Ltd (NYSE:CCM) fell 24.4% to $4.15 in pre-market trading after dipping 6% on Friday.
- Addex Therapeutics Ltd – ADR (NASDAQ:ADXN) dipped 15.6% to $9.23 in pre-market trading after gaining 28% on Friday.
- Exelixis Inc (NASDAQ:EXEL) fell 8.3% to $36.00 after the company announced detailed results from Phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in combination with an immune checkpoint inhibitor in metastatic colorectal cancer presented at ESMO 2025 and published in The Lancet.
- Cellectis SA (NASDAQ:CLLS) fell 7.3% to $3.69 in pre-market trading.
- Alumis Inc (NASDAQ:ALMS) declined 6.7% to $4.19 in pre-market trading.
- Nanobiotix SA – ADR (NASDAQ:NBTX) fell 6.3% to $23.98 in pre-market trading after declining 4% on Friday.
- Genmab A/S – ADR (NASDAQ:GMAB) declined 4.1% to $31.81 in pre-market trading. Genmab’s Rinatabart Sesutecan achieved 50% objective response rate and two complete responses in advanced endometrial cancer.
- Taysha Gene Therapies Inc (NASDAQ:TSHA) fell 4% to $4.53 in pre-market trading.
Now Read This:
Photo via Shutterstock
Contact Us
Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.